162
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Resistance phenotypes and susceptibility of contemporary Serratia isolates in the university hospital of Crete, Greece

, , , , , & show all
Pages 847-853 | Received 22 Mar 2017, Accepted 19 Jul 2017, Published online: 02 Aug 2017
 

Abstract

Objective: To study changes in the susceptibility of Serratia spp. in Crete, Greece (2010–2015).

Methods: Non-duplicate isolates were examined using automated systems. Phenotypic confirmatory tests were applied.

Results: Three hundred and seventy-eight Serratia spp. were analyzed. Serratia marcescens (88.3%) was the predominant species. Fluoroquinolones (97.9%), carbapenems (97.4%) and fosfomycin (97.4%) were the most active followed by amikacin (95.5%), piperacillin/tazobactam (94.7%), and trimethoprim/sulfamethoxazole (94.4%). The activity of 3rd and 4th generation cephalosporins was 87–88.6%. The distribution of multi-drug resistant (MDR) strains varied, with a trend towards increasing frequency. ESBL (7.9%), carbapenemase (2.9%), AmpC (2.1%) and aminoglycoside modifying enzyme (10.6%) production were the commonest resistant phenotypes.

Conclusion: The susceptibility of Serratia spp. varied during the study period a trend towards decreasing susceptibility, especially for non-carbapenem β-lactams and aminoglycosides.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.